前列腺癌非编码RNA1在前列腺癌诊断与鉴别诊断中的价值
| 作者: |
1于丹,
1勇逸欣,
1丁可,
1徐浪,
1蒋欣熠,
1,2李世宝
1 徐州医科大学医学技术学院，江苏 徐州 221000 2 徐州医科大学附属医院检验科，江苏 徐州 221000 |
| 通讯: |
李世宝
Email: sdjnshlb@xzhmu.edu.cn |
| DOI: | 10.3978/j.issn.2095-6959.2019.08.012 |
| 基金: | 国家级大学生创新训练计划项目(201810313024)；江苏省高等学校大学生实践创新训练计划重点项目(201810313025Z)；基础医学国家级实验教学示范中心(徐州医科大学)。 |
摘要
目的：探讨前列腺癌(prostate cancer，PCA)非编码RNA1(PRNCR1)在PCA早期诊断及与前列腺增生(benign prostate hyperplasia，BPH)鉴别诊断中的价值。方法：选取血清PSA水平增高的65例患者为研究对象，其中29例确诊PCA患者，31例BPH患者，5例PCA术后患者。应用实时荧光定量聚合酶链反应(quantitative polymerase chain reaction，qRT-PCR)检测血清中PRNCR1表达水平，分析PRNCR1在不同组别中的表达差异，探究其在PCA诊断中的临床应用价值。结果：PRNCR1在PCA组表达水平明显高于BPH组(P<0.05)，PCA组与PCA术后组表达差异无统计学意义(P>0.05)。ROC曲线分析结果显示：PSA的曲线下面积为0.808，敏感度为82.8%，特异度为61.3%；PRNCR1的曲线下面积为0.810，敏感度65.5%，特异度74.2%；两者联合诊断曲线下面积为0.899，敏感度为75.9%，特异度为96.8%。结论：PRNCR1在PCA中表达水平明显增高，提示PRNCR1在PCA诊断中具有潜在价值。
关键词：
前列腺癌；前列腺癌非编码RNA1；qRT-PCR；诊断；鉴别诊断
Role of non-coding RNA1 in the diagnosis and differential diagnosis of prostate cancer
CorrespondingAuthor: LI Shibao Email: sdjnshlb@xzhmu.edu.cn
DOI: 10.3978/j.issn.2095-6959.2019.08.012
Foundation: This work was supported by the National College Student Innovation Training Program (201810313024), Key Project of Practical Innovation Training Program for College Students in Jiangsu Province (201810313025Z)
Abstract
Objective: To evaluate the value of PRNCR1 in early diagnosis of prostate cancer and differential diagnosis of prostate hyperplasia. Methods: Sixty-five patients with elevated serum PSA levels were selected as the study subjects, including 29 patients with confirmed prostate cancer (PCA), 31 patients with prostate hyperplasia (BPH), and 5 patients with postoperative prostate cancer. Real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression level of PRNCR1 in serum, analyze the expression difference of PRNCR1 in different groups, and explore its clinical application value in the diagnosis of prostate cancer. Results: The expression level of PRNCR1 in the PCA group was significantly higher than that in the BPH group (P<0.05), and there was no statistically significant difference between the prostate cancer group and the prostate cancer postoperative group (P>0.05). The ROC curve analysis results showed that the area under the PSA curve was 0.808, with a sensitivity of 82.8% and a specificity of 61.3%. The area under the PRNCR1 curve was 0.810, with a sensitivity of 65.5% and a specificity of 74.2%. The area under the combined diagnosis curve was 0.899, the sensitivity was 75.9%, and the specificity was 96.8%. Conclusion: PRNCR1 expression significantly increases in the prostate cancer, suggesting the potential value of PRNCR1 in the diagnosis of PCA.
Keywords：
prostate cancer; prostate cancer non-coding RNA1; qRT-PCR; diagnosis; differential diagnosis